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Serum Soluble ST2
A Potential Novel Mediator in Left Ventricular
and Infarct Remodeling After Acute Myocardial Infarction
Robin A. P. Weir, MBCHB (HONS), BSC (HONS), MD,* Ashley M. Miller, PHD,†
Grace E. J. Murphy, MBCHB, BMEDSCI (HONS),† Suzanne Clements, RGN,* Tracey Steedman, BSC,*
John M. C. Connell, PHD,‡ Iain B. McInnes, PHD,† Henry J. Dargie, MD,* John J. V. McMurray, MD*
Glasgow, Scotland
Objectives This study sought to assess, for the first time, the relationship between serum concentrations of the soluble
interleukin-1 receptor family member ST2 (sST2) and serial change in left ventricular (LV) function after acute
myocardial infarction (AMI).
Background Serum sST2 levels are elevated early after AMI and are associated with lower pre-discharge LV ejection fraction
and adverse cardiovascular outcomes.
Methods The sST2 levels were measured in 100 patients (mean age 58.9  12.0 years; 77% male), admitted with AMI
with resultant LV systolic dysfunction, at baseline and at 12 and 24 weeks. Patients underwent cardiac mag-
netic resonance imaging and measurement of N-terminal pro-brain natriuretic peptide, norepinephrine, and aldo-
sterone at each time point.
Results Median sST2 decreased from 263.3 pg/ml at baseline to 140.0 pg/ml at 24 weeks (p  0.001). Serum sST2
correlated significantly with LV ejection fraction at baseline (r  0.30, p  0.002) and 24 weeks (r  0.23,
p  0.026); change in sST2 correlated with change in LV end-diastolic volume index (r  0.24, p  0.023).
Level of sST2 was positively associated with infarct volume index at baseline (r  0.26, p  0.005) and 24
weeks (r  0.22, p  0.037), and with change in infarct volume index (r  0.28, p  0.001). Level of sST2
was significantly higher in patients with greater infarct transmurality and endocardial extent, and in the presence
of microvascular obstruction. Level of sST2 correlated significantly with norepinephrine and aldosterone, but not
with N-terminal pro-brain natriuretic peptide.
Conclusions Measurement of sST2 early after AMI assists in the prediction of medium-term LV functional recovery. Novel re-
lationships were observed between sST2, infarct magnitude/evolution, and aldosterone. Serum sST2 may be of
pathophysiological importance in ventricular and infarct remodeling after AMI. (Effects of Eplerenone on Left
Ventricular Remodelling Following Heart Attack; NCT00132093) (J Am Coll Cardiol 2010;55:243–50) © 2010
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.047e
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aisk stratification of patients admitted with acute coronary
yndromes is increasingly dependent on measurement of
rognostically significant biomarkers. Serum ST2 (interleu-
in [IL]-1 receptor-like 1, OMIM *601203), a member of
he IL-1 receptor family with transmembrane (ST2L) and
oluble (sST2) isoforms, may be such a biomarker (1). The
ransmembrane ST2 isoform is membrane-bound with 3
rom the *Cardiology Department, Western Infirmary, †Division of Immunology,
nfection, and Inflammation, Glasgow Biomedical Research Centre, and the ‡MRC
lood Pressure Group, Glasgow Cardiovascular Research Centre, University of
lasgow, Glasgow, Scotland, United Kingdom. Funding for this study was received
rom Pfizer UK, Ltd., Surrey, England. Dr. Miller is supported by a BHF
ntermediate Basic Science Research Fellowship (FS/08/035/25309).l
Manuscript received March 21, 2009; revised manuscript received July 13, 2009,
ccepted August 3, 2009.xtracellular immunoglobulin-G domains, a single trans-
embrane domain, and an intracellular domain homolo-
ous to toll-like receptors and other IL-1 receptors (2).
See page 251
oluble ST2 lacks the transmembrane and intracellular
omains and is thought to function as a decoy receptor,
hich neutralizes IL-33, recently demonstrated to be its
igand (3). IL-33 exerts antihypertrophic effects in cultured
ardiomyocytes that are antagonized by administration of
ST2, and reduces myocardial fibrosis and cardiomyocyte
ypertrophy after experimental pressure overload in mice,
lthough interestingly, these effects are not seen in mice
acking the ST2 gene (4,5). These data suggest a possible
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Serum Soluble ST2 Post-MI Remodeling January 19, 2010:243–50cardioprotective role for the IL-33/
ST2 signaling pathway. In hu-
man studies, serum sST2 is ele-
vated early after acute myocardial
infarction (AMI) and correlates with
creatine kinase and (inversely with)
left ventricular ejection fraction
(LVEF) (2). Serum sST2 corre-
lates with N-terminal pro-brain
natriuretic peptide (NT-proBNP)
in patients admitted with ST-
segment elevation myocardial in-
farction (STEMI) and predicts
subsequent 30-day mortality and
heart failure (6,7). Additionally,
serum sST2 is elevated and is of
predictive value in acutely dyspneic
patients with and without decom-
pensated acute heart failure, and in
chronic heart failure (5,8,9).
That sST2 predicts adverse car-
diovascular outcome, and is related
to LVEF after AMI, suggests that
it may have a role in adverse left
ventricular (LV) remodeling, but
this has yet to be evaluated. We,
therefore, examined the relation-
ships between serum sST2, pa-
rameters of LV function, and a
variety of circulating mediators in a
cohort of patients admitted with
AMI.
ethods
atients. The subjects of this study were participants in a
andomized, double-blinded, placebo-controlled clinical trial
nvestigating the effects of eplerenone on LV remodeling after
MI in patients with left ventricular systolic dysfunction
LVSD) (10). Inclusion criteria were as follows:18 years of
ge; able to provide written, informed consent; admitted
ith AMI in the 1 to 14 days before enrollment; and LVEF
40% on screening transthoracic echocardiography—
impson’s biplane rule. Exclusion criteria were clinical or
adiological heart failure (Killip score 1); established
iabetes mellitus; pregnancy; serum creatinine 220
mol/l; serum potassium 5 mmol/l; and conventional
ontraindications to cardiac magnetic resonance (CMR).
he study complies with the Declaration of Helsinki, and
as approved by the local ethics committee.
rocedures. Eligible patients had venous blood collected
after 20 min of supine rest) for measurement of blood
hemistry, sST2, NT-proBNP, norepinephrine, and aldoste-
one, after which contrast-enhanced cardiac magnetic reso-
ance (ceCMR) imaging was performed. Patients were then
andomly assigned to double-blind eplerenone or placebo, with
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
ceCMR  contrast-
enhanced cardiac magnetic
resonance
CMR  cardiac magnetic
resonance
IL  interleukin
LV  left ventricle/
ventricular
LVEDVI  left ventricular
end-diastolic volume index
LVEF  left ventricular
ejection fraction
LVESVI  left ventricular
end-systolic volume index
LVMI  left ventricular
mass index
LVSD  left ventricular
systolic dysfunction
MBL  Medical and
Biological Laboratories
MVO  microvascular
obstruction
NT-proBNP  N-terminal
pro-brain natriuretic peptide
sST2  soluble ST2
STEMI  ST-segment
elevation myocardial
infarctionepeat ceCMR and biomarker sampling at 12 and 24 weeks. deasurement of circulating biomarkers. Blood was col-
ected in chilled tubes containing potassium ethylenediamine
etra-acetic acid (1 mg/ml blood) and aprotinin (50 KIU/ml
lood) for NT-proBNP, lithium heparin (20 U/ml) tubes for
orepinephrine and aldosterone, and in plain tubes (and
llowed to clot) for sST2, at room temperature. Samples were
hen centrifuged at 3,000 rpm for 15 min at ambient temper-
ture, and the supernatant immediately frozen and stored at
70°C until later blinded batched analysis. The NT-proBNP,
orepinephrine, and aldosterone samples were subjected to 1,
nd sST2 samples to 2, freeze-thaw cycles. The NT-proBNP
as measured using a chemiluminescent assay kit (Roche
iagnostics, West Sussex, United Kingdom) on an Elecsys
010 autoanalyzer (coefficient of variation 2%, limit of
etection of 5 pg/ml). Plasma norepinephrine was assayed by
igh-performance liquid chromatography and electrochemical
etection (within and between assay coefficient of variation
oth 10%; normal range in healthy volunteers 4 nmol/l).
lasma aldosterone concentration was measured using a solid
hase (coated tube) radioimmunoassay kit (Diagnostic Prod-
cts Corporation UK Ltd., Gwynedd, United Kingdom).
ntrabatch and interbatch precision was10% over the sample
oncentration range. Serum sST2 was quantified using a
uman IL-1 R4/ST2 enzyme-linked immunosorbent assay
R&D Systems, Abingdon, United Kingdom), with coefficient
f variation 5% and a lower limit of detection of 32 pg/ml.
eCMR protocol. ceCMR was performed using a 1.5-T
iemens (Erlangen, Germany) Sonata with a phased-array
hest coil, during breath-hold, and gated to the electrocar-
iogram. A steady-state free-precession sequence was used
o acquire a short-axis cine stack of the LV from base to
pex of 8-mm thick slices with a 2-mm interslice gap.
adolinium diethylenetriaminepenta-acetate (GE Health-
are, Waukesha, Wisconsin) was then administered (0.1
mol/kg) as a rapid intravenous bolus. After a 15-min
elay, a contrast-sensitive segmented inversion recovery
equence was used to acquire a second stack of short-axis
mages (positions copied from the cine stack), of thickness 8
m, with interslice gap 2 mm; the time to inversion was
aried within the range 200 to 300 ms to obtain optimal
ulling of the myocardium for the delayed enhancement
equences.
ONTRAST-ENHANCED CMR ANALYSIS. Post-processing
as performed using Argus software (Siemens, Erlangen,
ermany). Manual planimetry, performed by 1 observer
linded to treatment allocation, was used to trace the
picardial and endocardial contours of each short-axis slice
cquired in the cine-stack, allowing calculation of LV
olumes, LVEF, and LV mass. Infarcted LV myocardium
n ceCMR was defined as regional delayed hyperenhance-
ent after gadolinium injection involving at least the
ubendocardium. Using standardized contrast settings, the
nfarcted volume of LV myocardium, defined as any region
f signal intensity higher than normal (remote) myocar-
ium, was delineated manually by 1 observer blinded to
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January 19, 2010:243–50 Serum Soluble ST2 Post-MI Remodelingreatment allocation. In addition, on the initial (acute)
eCMR scan only, the anatomical location, transmurality,
nd endocardial extent of the infarct were recorded, as was
he presence or absence of late microvascular obstruction
MVO).
The anatomical location of the infarct was based on the
merican Heart Association standardized 17-segment
odel (11). Infarct location was categorized as anterior,
ateral, or inferior, defined as the location containing the
ighest percentage of infarcted myocardium. If the infarct
ncompassed equivalent anterior and lateral or inferior and
ateral segments, the site was classified as anterolateral or
nferolateral, respectively. Infarct transmurality score was
alculated by visually deciding the transmural extent per
egment in quarters (1  1% to 25%, 2  26% to 50%, 3 
1% to 75%, 4  76% to 100%) and calculating the mean
12). Endocardial extent of the infarct was defined as the
ean of the circumferential extent of the infarct at each of
he 3 short-axis slices used in the American Heart Associ-
tion model (11). Late MVO was defined as late hypoen-
ancement within a hyperenhanced region on the delayed
eCMR images that persisted for 10 min after contrast
njection (13).
tatistics. The ceCMR measurements were adjusted for
otal body surface area, creating the following indexed
uantities: left ventricular end-systolic volume index
LVESVI), left ventricular end-diastolic volume index
LVEDVI), left ventricular mass index (LVMI), and LV
nfarct volume index. Only patients with both a baseline and
4-week follow-up scan were analyzed; patients with an
ncomplete dataset were excluded. Left ventricular remod-
ling was defined as an increase over time of 10 ml/m2 in
VESVI and/or LVEDVI, as described previously (14,15).
ll baseline biomarker measurements were taken before
andomization, and serial biomarker data were initially
nalyzed regardless of parent study treatment allocation,
hen by treatment group. Normally distributed continuous
ata are expressed as mean values (SD). Non-normally
istributed continuous data are expressed as median (inter-
uartile range). Differences between mean values were
nalyzed using the Student t test, and those between median
alues by the Mann-Whitney U test. Paired comparisons in
iomarker concentrations over time were performed using
he Wilcoxon matched-pairs signed-rank test.
Non-normal data were logarithmic-transformed before
orrelative analysis; Pearson’s and Spearman’s correlation
oefficients were used for parametric and nonparametric
ariables, respectively. All statistical analyses were per-
ormed using SPSS version 15.0 (SPSS Inc., Chicago,
llinois). A probability value of p  0.05 was considered
ignificant.
esults
aseline characteristics are shown in Table 1. The mean time
rom AMI to screening transthoracic echocardiography was [4 h, and mean time to the first ceCMR scan was 97 h;
iomarker sampling was performed at a mean 46 h after AMI.
aired analysis of both ceCMR and biomarker results was
erformed in the 93 patients who completed the entire
4-week follow-up (3 died, 4 withdrew).
hanges in biomarker concentrations after AMI. Serum
ST2 concentration, expressed as median (interquartile range
aseline Characteristics of PatientsTable 1 Baseline Characteristics of Patients
AMI Cohort
(n  100)
Patient demographics
Age, yrs 58.9 (12.0)
Male 77
Medical history
Previous MI 7.0
Previous CABG 5.0
Previous PCI 2.0
Angina 37.0
Current smoker 55.0
Hypertension 35.0
Hypercholesterolemia* 25.0
Asthma/COPD 4.0
Infarct type/site
STEMI 90.0†
Non-STEMI 10.0‡
Infarct characteristics
Infarct volume index, ml/m2 34.0 (21.2)
Endocardial extent 36.8 (11.5)
Transmurality score 3.3 (0.6)
Late microvascular obstruction 56.0
Treatment
Thrombolysis 54.0
Primary PCI 27.0
Rescue PCI 26.0
Angiography performed 85.0
PCI performed 74.0
Biochemistry
Serum creatinine, mg/dl 1.13 (0.24)
Serum sST2, pg/ml, median (IQR) 263.3 (139.4–491.5)
NT-proBNP, pg/ml, median (IQR) 1,883 (997–3,181)
Norepinephrine, mmol/l, median (IQR) 2.90 (1.90–3.78)
Aldosterone, pmol/l, median (IQR) 131.0 (69.0–290.0)
Discharge medication
Aspirin 96.0
Clopidogrel 82.0
Beta-blocker 93.0
ACE inhibitor or ARB 94.0
Statin 98.0
Furosemide 21.0
Eplerenone 50.0
nless otherwise stated, continuous data are expressed as mean (SD), and categorical data are
xpressed as percentages of the relevant treatment group. *Serum cholesterol5 mmol/l and/or
eceiving lipid-lowering therapy before admission. †47 anterior  lateral, 39 inferior  lateral,
lateral. ‡8 anterior  lateral, 2 inferior  lateral.
ACE  angiotensin-converting enzyme; AMI  acute myocardial infarction; ARB  angiotensin-
eceptor blocker; CABG  coronary artery bypass graft surgery; COPD  chronic obstructive
ulmonary disease; IQR interquartile range; MImyocardial infarction; NT-proBNP N-terminal
ro-brain natriuretic peptide; PCI  percutaneous coronary intervention; STEMI  ST-segment
levation myocardial infarction.IQR]), decreased significantly (from 263.3 pg/ml [IQR 139.4
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Serum Soluble ST2 Post-MI Remodeling January 19, 2010:243–50o 491.5 pg/ml] at baseline to 140.0 pg/ml [IQR 83.0 to 196.2
g/ml] at 24 weeks; p  0.001). This decrease occurred
redominantly between baseline and 12 weeks (Fig. 1).
Over the 24 weeks of follow-up, plasma NT-proBNP
oncentration decreased significantly (from 1,883 pg/ml
IQR 997 to 3,181 pg/ml] to 335 pg/ml [IQR 177 to 728
g/ml]; p  0.001), as did norepinephrine (2.90 mmol/l
IQR 1.90 to 3.80 mmol/l] vs. 2.50 mmol/l [IQR 1.80 to
.50 mmol/l]; p  0.013); plasma aldosterone did not vary
ignificantly (131 pmol/l [IQR 69 to 290 pmol/l] at baseline
s. 153 pmol/l [IQR 86 to 287 pmol/l] at 24 weeks; p 
.33).
erum sST2 concentration and LV function after
MI. Serum sST2 concentrations were non-normally dis-
ributed and, accordingly, were logarithmic-transformed
efore analysis. The change over time in each measured
eCMR parameter is shown in Table 2. Baseline sST2
orrelated inversely with baseline LVEF (r  0.30, p 
.002) and baseline infarct volume index (r  0.26, p 
.005) but not with baseline LVESVI, LVEDVI, or LVMI
Table 3). Baseline sST2 correlated significantly with 24-
eek LVEF (r  0.23, p  0.026) and infarct volume
ndex (r  0.22, p  0.037) but not with 24-week LV
olumes or LVMI. Baseline sST2 correlated inversely with
hange in () infarct volume index (r  0.28, p  0.009)
ut not with change in any other ceCMR parameter.
Change in sST2 from baseline to 24 weeks correlated
ignificantly with LVEDVI (r  0.24, p  0.023) and
ith change in infarct volume index (r  0.21, p  0.043)
ut not with LVESVI, LVEF, or LVMI (Table 3).
Comparison of baseline sST2 concentration in patients
ith LVESVI 10 ml/m2 (n  16) and patients with
LVESVI 10 ml/m2 (n  77) revealed a trend toward a
Figure 1 Serial Change in Median sST2 Over Time After AMI
Serial changes in median serum soluble ST2 (sST2) over time after acute myo-
cardial infarction (AMI) are shown. Boxes represent interquartile ranges.igher sST2 in the former group, namely, patients in whom
d
semodeling occurred (379.6 pg/ml [IQR 201.4 to 615.5
g/ml] vs. 181.4 pg/ml [IQR 118.1 to 228.8 pg/ml],
espectively; p  0.054). Baseline sST2 was significantly
igher in patients (n  29) with LVEDVI 10 ml/m2
han in patients (n  64) with LVEDVI 10 ml/m2
358.0 pg/ml [IQR 259.7 to 647.1 pg/ml] vs. 197.5 pg/ml
IQR 129.2 to 393.6 pg/ml]; p  0.041).
erum sST2 concentration and infarct characteristics.
aseline infarct characteristics are shown in Table 1. There
ere no significant differences in serum sST2 between
nterior/anterolateral (n  55; 278.6 pg/ml [IQR 151.4 to
93.6 pg/ml]), inferior/inferolateral (n  41; 261.2 pg/ml
IQR 127.2 to 569.5 pg/ml]), and lateral (n  4; 181.8
g/ml [IQR 116.4 to 181.8 pg/ml]) sites of infarction (Fig.
A). Serum sST2 correlated significantly with the endocar-
ial extent of the infarct (r  0.26, p  0.008). The
resence of late MVO was associated with a significantly
igher serum sST2 (347.6 pg/ml [IQR 192.3 to 631.0
g/ml] vs. 185.7 pg/ml [IQR 126.5 to 330.3 pg/ml] without
VO; p  0.001) (Fig. 2B). Serum sST2 was significantly
igher in patients with a transmurality score at or above the
edian compared with patients whose score was below the
edian (289.3 pg/ml [IQR 183.0 to 580.1 pg/ml] vs. 203.8
g/ml [IQR 126.3 to 335.5 pg/ml]; p  0.031) (Fig. 2C).
erum sST2 and biochemical correlates after AMI. The
elationships between baseline NT-proBNP, norepineph-
ine, and aldosterone and ceCMR parameters are shown in
able 3. Baseline sST2 correlated significantly with baseline
orepinephrine (r  0.21, p  0.034) and aldosterone (r 
.28, p  0.006) but not with NT-proBNP (r  0.14, p 
.15). Baseline sST2 also correlated with norepinephrine
r  0.25, p  0.014) but not with aldosterone or
NT-proBNP.
Change in sST2 correlated significantly with aldoste-
one (r  0.26, p  0.012) and norepinephrine (r  0.23,
 0.024) but not with NT-proBNP (r  0.15, p  0.14).
reatment effect of eplerenone. Eplerenone had no sig-
ificant effect on serum sST2 concentration over time.
aseline serum sST2 concentration was similar within both
andomization groups (272.4 pg/ml [IQR 151.1 to 528.6
g/ml] in the placebo group vs. 259.1 pg/ml [IQR 129.7 to
10.1 pg/ml] in the eplerenone group; p  0.78). Over 24
eeks, the change in serum sST2 concentration was 66.4
erial ceCMR Parameters of Left Ventricularunction for Entire Study Cohort (n  100)Table 2 Serial ceCMR Paramet rs of Left VentricularFunction for Entire Study Cohort (n  100)
ceCMR Parameter Baseline 12 Weeks 24 Weeks p Value*
LVESVI, ml/m2 43.6 (15.2) 43.3 (20.9) 43.1 (20.7) 0.77
LVEDVI, ml/m2 83.9 (18.0) 89.4 (25.6) 88.1 (23.0) 0.011
LVEF, % 48.7 (8.8) 53.4 (10.4) 53.0 (12.0) 0.001
LVMI, g/m2 74.4 (15.3) 67.6 (15.8) 67.1 (14.3) 0.001
Infarct volume index,
ml/m2
34.0 (21.2) 22.2 (14.4) 20.9 (12.9) 0.001
ll values presented as mean (SD). *Comparison between baseline value and 24-week value.
ceCMR  contrast-enhanced cardiac magnetic resonance; LVEDVI  left ventricular end-
iastolic volume index; LVEF  left ventricular ejection fraction; LVESVI  left ventricular end-
ystolic volume index; LVMI  left ventricular mass index.
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January 19, 2010:243–50 Serum Soluble ST2 Post-MI Remodelingg/ml (IQR 226.2 to 10.1 pg/ml) in the placebo group
nd 130.7 pg/ml (IQR 409.3 to 228.0 pg/ml) in the
plerenone group (p  0.13).
To determine whether an interaction exists between
plerenone therapy and sST2, we divided patients into 4
roups according to baseline sST2 concentration and pla-
ebo/eplerenone therapy—sST2 less than median, placebo
herapy (“low sST2/plac”); sST2 less than median,
plerenone therapy (“low sST2/epl”); sST2 median or
reater, placebo therapy (“high sST2/plac”); and sST2
edian or greater, eplerenone therapy (“high sST2/epl”)—
nd compared remodeling outcomes (Table 4). There were
elatively small changes in LVESVI and LVEDVI in the
ow sST2 groups, and adverse remodeling (i.e., increases in
entricular volumes) only occurred in the high sST2 patients
reated with placebo. These increases appeared to be atten-
ated in high sST2 patients treated with eplerenone.
Eplerenone treatment was associated with a significant
ncrease in aldosterone over time (aldosterone 10.1
mol/l [IQR 135.0 to 85.0 pmol/l] in placebo group vs.
41.0 pmol/l [IQR 29.5 to 217.0 pmol/l] in eplerenone
roup; p  0.038) but had no significant effect on NT-
roBNP or norepinephrine compared with placebo. In the
arent study, eplerenone had a modest antiremodeling
ffect, but only after covariate adjustment (10).
iscussion
n our cohort of patients, all of whom were required to have
epressed LVEF, we have not only confirmed that there is
pearman Correlation Coefficients for Circulating Biomarkers,ampled at Baseline, and ceCMR Pa ameters of LV RemodelingTable 3 Sp arman Corr lation Coeffici nts for Circulating BiomSampled at Baseline, and ceCMR Parameters of LV Re
log10 (Serum sST2) log10 (NT
Baseline
LVESVI 0.17 0.3
LVEDVI 0.01 0.1
LVEF 0.30† 0.3
LVMI 0.05 0.0
Infarct volume 0.26† 0.2
24 weeks
LVESVI 0.17 0.4
LVEDVI 0.06 0.3
LVEF 0.23† 0.4
LVMI 0.03 0.0
Infarct volume 0.22* 0.3
sST2‡
ceCMR parameter (0 to 24 weeks)
LVESVI, ml/m2 0.11 0.13 0.
LVEDVI, ml/m2 0.18 0.24* 0.
LVEF, % 0.01 0.01 0.
LVMI, g/m2 0.03 0.01 0.
Infarct volume, ml/m2 0.28† 0.21* 0.
p  0.05. †p  0.01. ‡Change in each biomarker between baseline and 24 weeks.
sST2  soluble ST2; other abbreviations as in Tables 1 and 2.relationship between sST2 and LV function early after aMI, but have also shown for the first time that sST2 is
ssociated with medium-term LV function, and addition-
lly, that sST2 is related to infarct magnitude and infarct
emodeling over time. We report novel data on potential
elationships between sST2, aldosterone, and norepineph-
ine after AMI. We also provide some evidence to support
he possibility that eplerenone may attenuate LV remodel-
ng in patients with higher sST2 concentrations (although
his analysis is limited by small numbers).
Both sST2 isoforms—ST2L and sST2—are transcrip-
ionally induced by the application of biomechanical strain
o rodent cardiomyocytes and cardiac fibroblasts in vitro
2,4). Not only is sST2 elevated in vivo after experimental
MI in mice, but it has also been shown to be elevated in
he serum of human subjects after AMI, in acute heart
ailure, and in chronic heart failure (2,4–9). When mea-
ured early after AMI, significant associations have been
ound between sST2, higher creatine kinase concentrations,
nd lower pre-discharge LVEF (2,7). Moreover, baseline
ST2 predicts 30-day occurrence of heart failure or death
fter STEMI and, when combined with NT-proBNP,
ignificantly improves risk stratification in this condition
6,7). sST2 is also of prognostic benefit for both acute heart
ailure and chronic heart failure, in which it is associated
ith poorer LV function and higher New York Heart
ssociation functional class (5,8,9). The relationship be-
ween sST2 and serial change in LV function after AMI has
ot previously been characterized. Using a gold standard
echnology for LV functional assessment, ceCMR, which
rs,
ling
Baseline
P) log10 (Norepinephrine) log10 (Aldosterone)
0.17 0.25*
0.10 0.15
0.22* 0.31†
0.23* 0.22*
0.17 0.39†
0.23* 0.34†
0.09 0.18
0.31† 0.41†
0.16 0.22*
0.17 0.41†
proBNP‡ Norepinephrine‡ Aldosterone‡
0.14 0.10 0.08 0.28† 0.23*
0.06 0.01 0.02 0.2 0.33†
0.08 0.15 0.12 0.21* 0.07
0.12 0.19 0.07 0.07 0.07
0.10 0.14 0.15 0.34† 0.19arke
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9
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Serum Soluble ST2 Post-MI Remodeling January 19, 2010:243–50or the first time on the relationship between sST2, LV
emodeling, and infarct characteristics after AMI.
In our study patients, who were all required to have
VSD after AMI, we found a significant correlation be-
ween sST2 (measured in the first few days after AMI) and
re-discharge LVEF, in keeping with recent clinical studies.
n the largest published study examining sST2 in AMI, a
orrelation (albeit weak) was found between sST2 and lower
VEF early after STEMI in 551 patients enrolled in the
LARITY–TIMI 28 (Clopidogrel as Adjunctive Reperfu-
ion Therapy–Thrombolysis In Myocardial Infarction 28)
rial (7). A similar relationship was seen in 69 predomi-
antly STEMI patients enrolled in the HEART (Healing
nd Early Afterload Reducing Therapy) study (2). Our
ndings, that baseline sST2 correlates with medium-term
24-week) LVEF and that greater adverse LV remodeling
as seen in patients with the highest baseline sST2, are
ovel. Whether sST2 has a pathophysiological role in
ost-infarction remodeling or whether it simply identifies a
opulation with poorer LV function who would be more
ikely to remodel, is unclear; data from infarct characteristics
nd biomarker analysis provide further insights.
We assessed the relationship between sST2, baseline
nfarct characteristics, and infarct evolution over time.
lthough we did not find any relationship with infarct
ocation, we have shown that sST2, measured early after
MI, was associated with greater baseline infarct volume,
orrelated with the endocardial extent of infarction, and was
igher in patients with greater infarct transmurality, all
arameters of large infarction. We also found that sST2 was
igher in patients displaying MVO, which is known to be
ssociated with greater baseline LV volumes, more signifi-
ant remodeling, and adverse cardiovascular outcome after
MI (16,17). Over time, we found a correlation between
ST2 and 24-week infarct volume, and an inverse relation-
hip with  infarct volume, which occurs as peri-infarct
dema resolves and the infarcted myocardium remodels
18). These data suggest an association between infarct
agnitude and serum sST2 release.
We observed a novel correlation between sST2 and
lasma aldosterone. Aldosterone has strong profibrotic ef-
ects on the heart—both reparative fibrosis in the infarct
one and reactive fibrosis in noninfarct myocardium—some
f which are thought to be mediated by mineralocorticoid
eceptor activation on cardiac fibroblasts (19,20). Aldoste-
one antagonism can attenuate or even reverse myocardial
brosis, with concomitant improvement in LV function
21,22). Significant improvements in cardiovascular out-
omes have been demonstrated using aldosterone antago-
ists in survivors of AMI with resultant LVSD and heart
ailure (or diabetes mellitus) and in advanced chronic heart
ailure (23,24). We observed statistically significant associ-
tions between plasma aldosterone and parameters of LV
emodeling in our cohort.
Comparison of baseline sST2 concentrations in our studyFigure 2 Serum sST2 and Infarct Characteristics After AMI
Comparison of serum soluble ST2 (sST2) concentrations after acute myocar-
dial infarction (AMI) according to (A) contrast-enhanced cardiac magnetic reso-
nance-measured anatomical infarct site (note: lateral infarct site not used in
comparative analysis with other infarct sites, as n  4), (B) presence of late
microvascular obstruction (MVO), and (C) median transmurality score (3.44).
Boxes represent interquartile ranges.ith published studies in patients with AMI and heart
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January 19, 2010:243–50 Serum Soluble ST2 Post-MI Remodelingailure is rendered difficult by not only variations in timing
f sST2 sampling but also by the analysis kits used, with
ost studies to date using a Medical and Biological Labo-
atories (MBL) assay (5–7,9,25). The R&D Systems assay
sed in this study has not been harmonized to the MBL
ssay; thus, the exact numerical values generated may not be
nterchangeable. It does appear, however, that the magni-
ude of sST2 elevation (in pg/ml using the R&D assay) in
his study is comparable to the sST2 concentrations (in
g/ml) measured using the MBL assay in such related
tudies, although direct numerical comparison is perhaps
isleading.
tudy limitations. The parent study was powered for CMR
nd points, hence the relatively small sample size (n  100)
10). Where relevant, we have acknowledged findings from
ore appropriately powered studies examining sST2 in
MI. The study was neither designed nor powered for
nalysis of effects of sST2 on remodeling or its interaction
ith biomarkers; therefore, these results should be treated as
ypothesis-generating only. Our results pertain only to
atients with LVSD after AMI, and cannot be generalized
o all post-MI patients. We sampled serum sST2 only once
n the early post-infarction phase, at a mean 46 h after AMI.
he precise temporal profile of serum sST2 concentration
fter AMI in humans has yet to be characterized, but data
rom the CLARITY–TIMI 28 trial show a small but
ignificant decrease in sST2 between admission with
TEMI and angiography 96 h later (7). We cannot assume
hat we measured “peak” sST2 after AMI, merely a “pre-
ischarge” serum concentration. We did not simultaneously
easure IL-33 and therefore cannot comment on the
L-33/sST2 ratio, but this is a clear focus for future research
n both AMI and heart failure. Serum sST2 concentrations
re elevated in noncardiac conditions including asthma,
rauma, sepsis, malignancy, and autoimmune disease; al-
hough we did not adjust for these conditions, they are only
pplicable to a very small number of our trial cohort and
ould thus be unlikely to influence our results (26). The
ignificant correlations between sST2, LV functional pa-
ameters, and neurohormones reported in this study are
odest and must therefore be interpreted with caution, but
t is noteworthy that our correlation coefficients are similar
n magnitude, if not higher, than those in published studies
omparison of Remodeling Outcomes According to Baseline sST2Table 4 Comparison of Remodeling Outcomes According to Ba
Group n
Baseline Va
Median sST2 (IQR) LV
Low/plac 22 150.8 (58.6–261.2) 50.3
Low/epl 26 132.8 (51.9–384.9) 35.2
High/plac 23 544.7 (265.4–1,876.4) 48.7
High/epl 22 423.8 (266.6–1,522.1) 42.4
sing univariate analysis of variance: *LVESVI significantly lower in “low/epl” group than in “low/p
n “low/plac” group (p  0.01); ‡LVEDVI significantly higher in “high/plac” group than in the oth
  change between baseline and 24 weeks; low/epl baseline sST2 less median, randomized
ST2 median or greater, randomized to eplerenone; high/plac  baseline sST2 median or greatef sST2 in patients with AMI and heart failure (2,8,9).inally, it must be appreciated that correlations between
easured quantities, as reported within this study, do not
mply definite biologic interaction.
onclusions
e have shown that measurement of sST2 early after AMI
ssists in the prediction of medium-term LV functional
ecovery after AMI, and that direct relationships exist
etween sST2, infarct magnitude, and infarct remodeling.
plerenone, which had a modest antiremodeling effect in
he parent study, may attenuate remodeling to a greater
xtent in patients with a higher baseline sST2 (10). We also,
or the first time, report on a relationship between sST2 and
irculating aldosterone, and suggest that the IL-33/sST2
ignaling system and the RAAS may be interlinked, raising
he possibility of a direct role for the IL-33/sST2 system in
he pathogenesis of post-infarction remodeling, which mer-
ts further study as the role of this novel biomarker is further
nraveled.
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